SITC 2021: Early-Phase Study Results of LN-145 Monotherapy in NSCLC
Posted: Friday, December 3, 2021
Adam Schoenfeld, MD, of Memorial Sloan Kettering Cancer Center, New York, and colleagues conducted the phase II IOV-COM-202 study to assess LN-145, an autologous tumor-infiltrating lymphocyte product, in patients with non–small cell lung cancer (NSCLC). During the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting (Abstract 458), these investigators reported the first efficacy and safety data.
“LN-145 was successfully manufactured, and one-time treatment produced an expected safety profile and durable responses in heavily pretreated patients with NSCLC, regardless of PD-L1 expression,” the study authors concluded. “The activity of LN-145 monotherapy is encouraging and warrants further investigation of LN-145 as a single-agent and in combination in patients with NSCLC in ongoing studies IOV-LUN-202 and IOV-COM-202 Cohorts 3A and 3C.”
This multicenter, open-label study enrolled 28 patients with metastatic or advanced NSCLC who were previously treated with immune checkpoint inhibitors into cohort 3B. Participants were administered nonmyeloablative lymphodepletion, LN-145 infusion, and no more than six doses of interleukin-2 (IL-2).
A total of 24 patients were evaluable for efficacy as of June 2021, all of whom received prior immune checkpoint inhibitors. Tumor-infiltrating lymphocytes were most often collected from lung metastases (57.1%).
The safety profile of LN-145 appeared to be consistent with known treatment-emergent adverse event profiles of IL-2 and nonmyeloablative lymphodepletion. Notably, more than 30% of patients experienced anemia and thrombocytopenia of grade 3 or higher.
The objective response rates among patients who were evaluable for efficacy and the entire population were 25.0% and 21.4%, respectively. With 83% of responses ongoing at the last follow-up, the median duration of response was not reached. However, two responses occurred in participants who had PD-L1–negative disease, and one had a complete metabolic response; all responders received at least two prior therapy lines. Of note, 26 individuals had tumor-infiltrating lymphocytes available for T-cell receptor repertoire analysis, with a mean of 13,142 unique clones.
Disclosure: No disclosure information was provided.